RPTX News and Press, Repare Therapeutics Inc. From 06/02/22

Gainers: Immix Biopharma (IMMX) +37%. Bright Green (BGXX) +29%. Repare Therapeutics (RPTX) +29%. Yumanity Therapeutics (YMTX) +24%. PDS Biotechnology (PDSB) +15%. Losers: Zosano Pharma (ZSAN) -48%. Immunic (IMUX) -41%. Aeglea BioTherapeutics (AGLE) -40%...

Repare Therapeutics (NASDAQ:RPTX) climbed ~17% in the post-market Wednesday after the clinical-stage precision oncology company announced a worldwide license and collaboration agreement with Swiss pharma giant Roche (OTCQX:RHHBY) (OTCQX:RHHBF) for its leading cancer candidate RP-350...

Repare will receive a $125 million upfront payment and is eligible to receive up to an additional $1.2 billion in potential development, regulatory, commercial and sales milestones, plus royalties on global net product sales Repare to host conference call today at ...

Repair Therapeutics (RPTX) shares trade higher after the 10% owner bought 420,000 shares at $8.50 worth ~$3.6M. Stock is up 9% in mid-day trading session. For further details see: Repair Therapeutics jumps 9% after $3.6M insider buying

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic L...

Repare Therapeutics press release (NASDAQ:RPTX): Q1 GAAP EPS of -$0.83 beats by $0.04. Revenue of $0.41M (+141.2% Y/Y) misses by $1.55M. For further details see: Repare Therapeutics GAAP EPS of -$0.83 beats by $0.04, revenue of $0.41M misses by $1.55M

Oral presentation of clinical data from the Phase 1/2 TRESR Trial of camonsertib (also known as RP-3500) monotherapy in solid tumors at 2022 AACR Annual Meeting Results demonstrated robust activity in ovarian cancer with a 75% CBR, 25% ORR and 35 weeks mPFS Results als...

Data show PKMYT1 inhibition is a promising therapeutic target in CCNE1-amplified cancers RP-6306, a first-in-class, oral PKMYT1 inhibitor, is currently being evaluated in Phase 1 clinical trials Repare Therapeutics Inc. (“Repare” or the “Company&...

The following slide deck was published by Repare Therapeutics Inc. in conjunction with this event. For further details see: Repare Therapeutics (RPTX) Presents at the American Association for Cancer Research Annual Meeting 2022 - Slideshow

RP-3500 shows robust activity in ovarian cancer demonstrating 75% CBR, with 25% ORR and mPFS of 35 weeks Updated monotherapy results show 43% CBR in solid tumors across genotypes, and potential best-in-class safety and tolerability Encouraging data in tumors harboring ...